NASDAQ:PHVS

Pharvaris B.v Stock Insider Trading

Healthcare > Biotechnology

Buy PHVS

*Your capital is at risk

$35.07

+0 (+0%)

At Close: Jul 13, 2026

Pharvaris B.V Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -96.52. In total, the insiders bought 328.17K and sold 356.42K PHVS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-96.52
● Buy	328.17K shares
● Sell	356.42K shares
51% Buy Activity Weak Positive Correlation
Sell Signal Medium Confidence Jun 30, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -96.52. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 30, 2026 Sell	Common Stock S-Sale	Schikan Johannes Gerardus Christiaan Petrus Director	Director	30 712 Value: $1.09M
Jun 30, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	30 703 Value: $1.09M
Jun 30, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	24 900 Value: $200.4K
Jun 30, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	2 972 Value: $8K
Jun 30, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	27 872 Value: $988.9K
Jun 30, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	24 900 Value: $200.4K
Jun 30, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	2 972 Value: $8K
Jun 29, 2026 Sell	Common Stock S-Sale	Schikan Johannes Gerardus Christiaan Petrus Director	Director	6 888 Value: $241.4K
Jun 29, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	6 997 Value: $245.2K
Jun 29, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	4 200 Value: $33.8K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	4 200 Value: $33.8K
Jun 29, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	8 300 Value: $290.9K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	900 Value: $7K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	1 400 Value: $4K
Jun 29, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	4 100 Value: $10.6K
Jun 29, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	2 300 Value: $80.8K
Jun 29, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	1 400 Value: $4K
Jun 29, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	4 100 Value: $10.6K
Jun 29, 2026 Sell	Common Stock S-Sale	Schikan Johannes Gerardus Christiaan Petrus Director	Director	2 400 Value: $84.2K
Jun 26, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lu Peng Chief Medical Officer	Officer	14 700 Value: $38.1K
Jun 26, 2026 Buy	Common Stock M-Exempt	Lu Peng Chief Medical Officer	Officer	14 700 Value: $38.1K
Jun 26, 2026 Sell	Common Stock S-Sale	Lu Peng Chief Medical Officer	Officer	14 700 Value: $499.8K
Jun 25, 2026 Sell	Common Stock S-Sale	Lesage Anne Chief Early Development	Officer	2 300 Value: $80.8K
Jun 25, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lesage Anne Chief Early Development	Officer	900 Value: $7K
Jun 25, 2026 Buy	Common Stock M-Exempt	Lesage Anne Chief Early Development	Officer	900 Value: $7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PHARVARIS B.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...

Read Full Profile Here